Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Global Oncology Pharmaceuticals Market
... targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues. The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate ... Read More
-
Asia-Pacific Multi-Cancer Early Detection Market, By Type (Liquid Biopsy, Gene Panel, LDT, & Others), By End-Use (Hospitals & Clinics, Diagnostics Laboratories, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F
... valued at USD 175.76 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.47% through 2029. The Asia Pacific Multi-Cancer Early Detection Market is a dynamic ... Read More
-
Acute Myeloid Leukemia (AML) Treatment Market in APAC 2024-2028
... the forecast period. The report on the acute myeloid leukemia (AML) treatment market in apac provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around ... Read More
-
UAE Genetic Testing Market By Type (Carrier Testing, Diagnostic Testing, New-born Screening, Predictive & Presymptomatic Testing, Prenatal Testing, Others), By Disease (Sickle Cell Anemia, Thalassemia, Huntington's Disease, Cancer, Others), By Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), By Service Providers (Clinical & Metabolic Specialists, Genetic Counsellors, Diagnostic Laboratories, Hospitals), By Region , By Competition, Forecast and Opportunities, 2019-2029F
... Molecular Testing), By Service Providers (Clinical & Metabolic Specialists, Genetic Counsellors, Diagnostic Laboratories, Hospitals), By Region , By Competition, Forecast and Opportunities, 2019-2029F UAE Genetic Testing Market was valued at USD 32.46 million in 2023 ... Read More
-
Saudi Arabia Genetic Testing Market By Type (Carrier Testing, Diagnostic Testing, New-born Screening, Predictive & Pre-symptomatic Testing, Prenatal Testing, Others), By Disease (Sickle Cell Anemia, Thalassemia, Huntington's Disease, Cancer, Others), By Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), By Service Providers (Clinical & Metabolic Specialists, Genetic Counsellors, Diagnostic Laboratories, Hospitals), By Region, Competition, Opportunity & Forecast, 2019-2029F
... Testing, Molecular Testing), By Service Providers (Clinical & Metabolic Specialists, Genetic Counsellors, Diagnostic Laboratories, Hospitals), By Region, Competition, Opportunity & Forecast, 2019-2029F Saudi Arabia Genetic Testing Market was valued at USD 0.27 billion in 2023 ... Read More
-
United States Veterinary Oncology Market By Animal Type (Canine, Feline, Equine), By Therapy (Radiotherapy, Surgery, Chemotherapy, Immunotherapy and Other Therapies), By Cancer Type (Skin Cancers, Lymphomas, Sarcomas and Others), By Region, Competition, Forecast & Opportunities, 2019-2029F
... 2019-2029F United States Veterinary Oncology Market was valued at USD 450.63 Million in 2023 and is expected to reach USD 644.03 Million by 2029 with a CAGR of 6.09% during the forecast period. The United ... Read More
-
Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029
... to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving ... Read More
-
Patient Derived Xenograft / PDX Models
... the year 2023, is expected to reach US$510.8 Million by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030. Pre-Clinical Drug Development Application, one of the segments analyzed in the report, is ... Read More
-
Cancer Stem Cells
... by 2030, growing at a CAGR of 8.3% over the analysis period 2023-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$1.3 ... Read More
-
Breast Cancer Liquid Biopsy
... reach US$1.1 Billion by 2030, growing at a CAGR of 21.4% over the analysis period 2023-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.0% CAGR and reach ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 13.7% over the analysis period 2023-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.1% ... Read More
-
Genomics in Cancer Care
... reach US$62.1 Billion by 2030, growing at a CAGR of 16.5% over the analysis period 2023-2030. Instruments, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$25.0 ... Read More
-
Hemato Oncology Testing
... by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030. Hemato Oncology Testing Services, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$8.6 ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2023-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record ... Read More
-
Gynecological Cancer Drugs
... by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Cervical Cancer Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$10.3 Billion ... Read More
-
Interventional Oncology Devices
... at a CAGR of 6.3% over the analysis period 2023-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.4 Billion by the end of ... Read More
-
Oncology Information Systems
... by 2030, growing at a CAGR of 6.1% over the analysis period 2023-2030. Software Component, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$5.5 Billion by ... Read More
-
Immunotherapy Drugs
... at a CAGR of 9.6% over the analysis period 2023-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$254.4 Billion by the end of ... Read More
-
Breakthrough Therapy (BT) Designation
... reach US$415.7 Billion by 2030, growing at a CAGR of 15.4% over the analysis period 2023-2030. Oncology Application, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach ... Read More
-
Global Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type (Pemetrexed and Combination, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Other Drug Types), By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)
... Forecast (2020-2030) Executive Summary Azoth Analytics has released a research report titled “Global Malignant Pleural Mesothelioma Market (2024 Edition)” which provides a Pemetrexed and Combination analysis of the Global Malignant Pleural Mesothelioma industry in terms ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.3% over the analysis period 2023-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the ... Read More
-
Non-Melanoma Skin Cancer
... by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 ... Read More
-
NDDS in Cancer Therapy
... reach US$73.2 Billion by 2030, growing at a CAGR of 20.8% over the analysis period 2023-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.7% CAGR and reach US$67.8 ... Read More
-
Immuno-Oncology
... of 16.2% over the analysis period 2023-2030. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$75.1 Billion by the end of the analysis ... Read More
Research Assistance
